Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (981) Arrow Down
Filter Results: (981) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (2,519)
    • Faculty Publications  (981)

    Show Results For

    • All HBS Web  (2,519)
      • Faculty Publications  (981)

      Treatment Of PrisonersRemove Treatment Of Prisoners →

      ← Page 5 of 981 Results →

      Are you looking for?

      →Search All HBS Web
      • December 2023
      • Article

      Association of Hospital System Affiliation with COVID-19 Capacity Burden

      By: Zachary Levin, Pinar Karaca-Mandic, Richard J. Boxer and Regina E. Herzlinger
      What is the message? The COVID-19 pandemic exposed the highly variable and uncoordinated responses by hospitals. The authors found that while the non-top ten system affiliated hospitals had a larger COVID-19 share index relative to independent hospitals, top-ten system... View Details
      Keywords: COVID-19 Pandemic; Resource Allocation; Health Pandemics; Demographics; Health Care and Treatment; Health Industry
      Citation
      Read Now
      Related
      Levin, Zachary, Pinar Karaca-Mandic, Richard J. Boxer, and Regina E. Herzlinger. "Association of Hospital System Affiliation with COVID-19 Capacity Burden." Health Management, Policy and Innovation 8, no. 3 (December 2023).
      • 2023
      • Article

      Balancing Risk and Reward: An Automated Phased Release Strategy

      By: Yufan Li, Jialiang Mao and Iavor Bojinov
      Phased releases are a common strategy in the technology industry for gradually releasing new products or updates through a sequence of A/B tests in which the number of treated units gradually grows until full deployment or deprecation. Performing phased releases in a... View Details
      Keywords: Product Launch; Mathematical Methods; Product Development
      Citation
      Read Now
      Related
      Li, Yufan, Jialiang Mao, and Iavor Bojinov. "Balancing Risk and Reward: An Automated Phased Release Strategy." Advances in Neural Information Processing Systems (NeurIPS) (2023).
      • 2024
      • Working Paper

      The Uneven Impact of Generative AI on Entrepreneurial Performance

      By: Nicholas G. Otis, Rowan Clarke, Solène Delecourt, David Holtz and Rembrand Koning
      Scalable and low-cost AI assistance has the potential to improve firm decision-making and economic performance. However, running a business involves a myriad of open-ended problems, making it difficult to know whether recent AI advances can help business owners make... View Details
      Keywords: AI and Machine Learning; Performance Improvement; Small Business; Decision Choices and Conditions; Kenya
      Citation
      SSRN
      Read Now
      Related
      Otis, Nicholas G., Rowan Clarke, Solène Delecourt, David Holtz, and Rembrand Koning. "The Uneven Impact of Generative AI on Entrepreneurial Performance." Harvard Business School Working Paper, No. 24-042, December 2023.
      • November 2023 (Revised April 2024)
      • Case

      BiomX: Bringing Phage Back to the Stage

      By: Paul A. Gompers, Elie Ofek, Orna Dan and Emilie Billaud
      In the spring of 2023, and following the favorable results of a trial involving its phage cocktail for treating lung infections among cystic fibrosis (CF) patients, the leadership of BiomX had several critical issues to wrestle with. First, given its precarious... View Details
      Keywords: Working Capital; Financing and Loans; Health Testing and Trials; Product Development; Research and Development; Science-Based Business; Commercialization; Biotechnology Industry; Pharmaceutical Industry
      Citation
      Educators
      Purchase
      Related
      Gompers, Paul A., Elie Ofek, Orna Dan, and Emilie Billaud. "BiomX: Bringing Phage Back to the Stage." Harvard Business School Case 524-051, November 2023. (Revised April 2024.)
      • October 2023
      • Case

      Hey Jane: Delivering Abortion Pills to the Doorstep

      By: Rembrand Koning, Geraldine Pena-Galea and Sarah Mehta
      This case tells the story of Hey Jane, a telehealth clinic founded in 2020 that provides virtual medication abortion services to eligible patients in nine U.S. states. By January 2023, the company had served more than 20,000 patients and raised nearly $10 million in... View Details
      Keywords: Operations; Business Startups; Health Care and Treatment; Growth and Development Strategy; Health Industry; Technology Industry; United States
      Citation
      Educators
      Purchase
      Related
      Koning, Rembrand, Geraldine Pena-Galea, and Sarah Mehta. "Hey Jane: Delivering Abortion Pills to the Doorstep." Harvard Business School Case 724-408, October 2023.
      • October 2023
      • Background Note

      What Leaders Need to Know about Mental Health

      By: Boris Groysberg, Robin Abrahams, Liana Groysberg, Natalia Groysberg and Abhijit Naik
      This paper will provide an overview of the nature of anxiety and depression, the particular vulnerabilities and stresses of CEOs, and suggestions for managing mental health in the workplace. View Details
      Keywords: CEO; Mental Health; Health Care and Treatment; Health Disorders; Leadership; Well-being
      Citation
      Educators
      Purchase
      Related
      Groysberg, Boris, Robin Abrahams, Liana Groysberg, Natalia Groysberg, and Abhijit Naik. "What Leaders Need to Know about Mental Health." Harvard Business School Background Note 424-032, October 2023.
      • 2023
      • Working Paper

      The Political Economy of a 'Miracle Cure': The Case of Nebulized Ibuprofen and Its Diffusion in Argentina

      By: Sebastian Calónico, Rafael Di Tella and Juan Cruz Lopez Del Valle
      We document the diffusion of nebulized ibuprofen in Argentina as a treatment for COVID-19. As the pandemic spread, this clinically unsupported drug reached thousands of patients, even some seriously ill, despite warnings by the regulator and medical societies. Detailed... View Details
      Keywords: COVID-19; Health Care and Treatment; Health Pandemics; Adoption; Behavior; Governing Rules, Regulations, and Reforms; Learning
      Citation
      Find at Harvard
      Register to Read
      Related
      Calónico, Sebastian, Rafael Di Tella, and Juan Cruz Lopez Del Valle. "The Political Economy of a 'Miracle Cure': The Case of Nebulized Ibuprofen and Its Diffusion in Argentina." NBER Working Paper Series, No. 31781, October 2023.
      • October 2023
      • Case

      Vida Health: Transforming Chronic Disease Treatment

      By: William Sahlman and Nicole Tempest Keller
      San Francisco based Vida Health, founded by Stephanie Tilenius, former vice president of Commerce and Payments at Google, was a B2B digital health startup focused on the treatment of cardiometabolic conditions, such as diabetes and obesity. Its innovative digital... View Details
      Keywords: Corporate Strategy; Growth and Development Strategy; Demand and Consumers; Health Care and Treatment; Product Marketing; Risk and Uncertainty; Technological Innovation; Health Industry; Technology Industry; United States; California; San Francisco
      Citation
      Educators
      Purchase
      Related
      Sahlman, William, and Nicole Tempest Keller. "Vida Health: Transforming Chronic Disease Treatment." Harvard Business School Case 824-001, October 2023.
      • 2023
      • Working Paper

      Are Hospital Quality Indicators Causal?

      By: Amitabh Chandra, Maurice Dalton and Douglas O. Staiger
      Hospitals play a key role in patient outcomes and spending, but efforts to improve their quality are hindered because we do not know whether hospital quality indicators are causal or biased. We evaluate the validity of commonly used quality indicators, such as... View Details
      Keywords: Quality; Health Care and Treatment; Measurement and Metrics; Outcome or Result; Health Industry
      Citation
      Find at Harvard
      Register to Read
      Related
      Chandra, Amitabh, Maurice Dalton, and Douglas O. Staiger. "Are Hospital Quality Indicators Causal?" NBER Working Paper Series, No. 31789, October 2023.
      • October 2023
      • Article

      Health System Perspective on Cost for Delivering a Decision Aid for Prostate Cancer Using Time-Driven Activity-Based Costing

      By: David R. Ho, Robert S. Kaplan, Jonathan Bergman, David F. Penson, Benjamin Waterman, Kristin C. Williams, Jefersson Villatoro, Lorna Kwan and Christopher S. Saigal
      Previsit decision aids (DAs) have been shown to improve decisional quality. But the cost to deploy a DA has not been previously estimated. We interviewed or observed relevant personnel at three institutions that had implemented DA programs for men with prostate cancer.... View Details
      Keywords: Time-Driven Activity-Based Costing; Health Care and Treatment; Cost Accounting; Health Industry
      Citation
      Read Now
      Related
      Ho, David R., Robert S. Kaplan, Jonathan Bergman, David F. Penson, Benjamin Waterman, Kristin C. Williams, Jefersson Villatoro, Lorna Kwan, and Christopher S. Saigal. "Health System Perspective on Cost for Delivering a Decision Aid for Prostate Cancer Using Time-Driven Activity-Based Costing." Medical Care 61, no. 10 (October 2023): 681–688.
      • September 2023
      • Teaching Note

      Roche: ESG and Access to Healthcare

      By: George Serafeim
      Teaching Note for HBS Case No. 123-075. In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first ESG investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal... View Details
      Keywords: ESG; Access To Care; Healthcare; Healthcare Access; Innovation; Social Impact; Affordable; Health Care and Treatment; Innovation and Invention; Product Development; Resource Allocation; Corporate Social Responsibility and Impact; Health Industry
      Citation
      Purchase
      Related
      Serafeim, George. "Roche: ESG and Access to Healthcare." Harvard Business School Teaching Note 124-028, September 2023.
      • September 2023
      • Supplement

      Fighting the Battle of the Bulge—Evaluating Do Good/Do Well Innovations in Morbid Obesity Treatment

      By: Regina E. Herzlinger
      This PowerPoint accompanies Regina E. Herzlinger's "Fighting the Battle of the Bulge – Evaluating Do Good/Do Well Innovations in Morbid Obesity Treatment" teaching note (HBS Case No.324-013) and is designed for instructors to use in the classroom when teaching this... View Details
      Keywords: Health Care Delivery; Obesity; Weight Loss; Innovation and Invention; Innovation and Management; Health Care and Treatment; Medical Specialties; Health Industry
      Citation
      Purchase
      Related
      Herzlinger, Regina E. "Fighting the Battle of the Bulge—Evaluating Do Good/Do Well Innovations in Morbid Obesity Treatment." Harvard Business School PowerPoint Supplement 324-016, September 2023.
      • September 2023
      • Teaching Note

      Fighting the Battle of the Bulge—Evaluating Do Good/Do Well Innovations in Morbid Obesity Treatment

      By: Regina E. Herzlinger
      Teaching Note for HBS Case No. 304-009. The case is part of the first module of the Innovating in Health Care course. Its purpose is to demonstrate how to evaluate the “do good” and do well” potential of a health care innovation. View Details
      Keywords: Innovation In Healthcare Delivery; Innovation; Obesity; Digital Health; Weight Loss; Health Care and Treatment; Innovation and Management; Business Model; Medical Specialties; Mission and Purpose; Health Industry
      Citation
      Purchase
      Related
      Herzlinger, Regina E. "Fighting the Battle of the Bulge—Evaluating Do Good/Do Well Innovations in Morbid Obesity Treatment." Harvard Business School Teaching Note 324-013, September 2023.
      • September–October 2023
      • Article

      Prospective Evaluation of the Cost of Performing Breast Imaging Examinations Using Time-Driven Activity-Based Costing Method: A Single Center Study

      By: Aamir Ali, Jordana Phillips, Damir Ljuboja, Syed S. Shehab, Etta D. Pisano, Robert S. Kaplan and Ammar Sarwar
      We use time-driven activity-based costing (TDABC) to measure the cost of performing breast imaging using different modalities: full-field digital mammography (FFDM), digital breast tomosynthesis (DBT), contrast-enhanced mammography (CEM), US and MRI exams, and... View Details
      Keywords: Time-Driven Activity-Based Costing; Health Care; Breast Cancer; Health Care and Treatment; Cost; Cost Accounting; Health Industry
      Citation
      Read Now
      Related
      Ali, Aamir, Jordana Phillips, Damir Ljuboja, Syed S. Shehab, Etta D. Pisano, Robert S. Kaplan, and Ammar Sarwar. "Prospective Evaluation of the Cost of Performing Breast Imaging Examinations Using Time-Driven Activity-Based Costing Method: A Single Center Study." Journal of Breast Imaging 5, no. 5 (September–October 2023): 546–554.
      • October 2023
      • Article

      What Does the Inflation Reduction Act Mean for Patients and Physicians?

      By: Amitabh Chandra and Benedic Ippolito
      The debate around prescription drug measures in the recently passed U.S. Inflation Reduction Act (IRA), which limit some patients’ out-of-pocket costs, has not fully addressed their effect on physicians and patients via their effect on payers. Reducing patients’ costs... View Details
      Keywords: Government Legislation; Price; Health Care and Treatment
      Citation
      Find at Harvard
      Purchase
      Related
      Chandra, Amitabh, and Benedic Ippolito. "What Does the Inflation Reduction Act Mean for Patients and Physicians?" NEJM Catalyst Innovations in Care Delivery 4, no. 10 (October 2023).
      • August 2023
      • Case

      Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company

      By: Satish Tadikonda and Brad Prosek
      Constellation Pharmaceuticals was a company focused on epigenetic therapies for cancer patients. Despite a promising start and an early deal with a leading biopharma company, the company weathered twin setbacks in the end of a major research collaboration and the... View Details
      Keywords: Mergers and Acquisitions; Health Care and Treatment; Organizational Change and Adaptation; Research and Development; Business Strategy; Partners and Partnerships; Goals and Objectives; Pharmaceutical Industry; United States
      Citation
      Educators
      Purchase
      Related
      Tadikonda, Satish, and Brad Prosek. "Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company." Harvard Business School Case 824-032, August 2023.
      • August 2023 (Revised May 2024)
      • Case

      Dicerna Pharmaceuticals: Decision Making in Clinical Trial Design and Operations

      By: Satish Tadikonda and Amanda McEwen
      The success or failure of Dicerna Pharmaceuticals (Dicerna) as an emerging pharmaceutical company would likely hinge on its lead drug candidate Nedosiran and the company’s ability to see it successfully through clinical development. Ralf Rosskamp, Chief Medical... View Details
      Keywords: Business Strategy; Health Testing and Trials; Product Development; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry
      Citation
      Educators
      Purchase
      Related
      Tadikonda, Satish, and Amanda McEwen. "Dicerna Pharmaceuticals: Decision Making in Clinical Trial Design and Operations." Harvard Business School Case 824-018, August 2023. (Revised May 2024.)
      • August 2023
      • Case

      Augmenix: Space to Think Differently

      By: Satish Tadikonda and Sidhant Jena
      Amar Sawhney, a serial medtech entrepreneur, had founded Augmenix to develop and commercialize a hydrogel-based medical device called SpaceOAR as an adjunctive technology to core radiation therapy. This technology was used to protect organs at risk (OAR) during... View Details
      Keywords: Entrepreneurship; Health Care and Treatment; Technology Adoption; Innovation Strategy; Technological Innovation; Product Development; Commercialization; Medical Devices and Supplies Industry
      Citation
      Educators
      Purchase
      Related
      Tadikonda, Satish, and Sidhant Jena. "Augmenix: Space to Think Differently." Harvard Business School Case 824-031, August 2023.
      • 2023
      • Article

      Evidence from the First Shared Medical Appointments (SMAs) Randomised Controlled Trial in India: SMAs Increase the Satisfaction, Knowledge, and Medication Compliance of Patients with Glaucoma

      By: Nazlı Sönmez, Kavitha Srinivasan, Rengaraj Venkatesh, Ryan W. Buell and Kamalini Ramdas
      In Shared Medical Appointments (SMAs), patients with similar conditions meet the physician together and each receives one-on-one attention. SMAs can improve outcomes and physician productivity. Yet privacy concerns have stymied adoption. In physician-deprived nations,... View Details
      Keywords: Health Care and Treatment; Customer Satisfaction; Outcome or Result; India
      Citation
      Read Now
      Related
      Sönmez, Nazlı, Kavitha Srinivasan, Rengaraj Venkatesh, Ryan W. Buell, and Kamalini Ramdas. "Evidence from the First Shared Medical Appointments (SMAs) Randomised Controlled Trial in India: SMAs Increase the Satisfaction, Knowledge, and Medication Compliance of Patients with Glaucoma." e0001648. PLoS Global Public Health 3, no. 7 (2023).
      • July 2023
      • Article

      Before or After? The Effects of Payment Decision Timing in Pay-What-You-Want Contexts

      By: Raghabendra P. KC, Vincent Mak and Elie Ofek
      We study how payment decision timing—before versus after product delivery—influences consumer payment under pay-what-you-want pricing. We focus on situations where there is minimal change in consumer uncertainty regarding the product before versus after receiving it.... View Details
      Keywords: Price; Behavior; Valuation; Philanthropy and Charitable Giving
      Citation
      Find at Harvard
      Purchase
      Related
      KC, Raghabendra P., Vincent Mak, and Elie Ofek. "Before or After? The Effects of Payment Decision Timing in Pay-What-You-Want Contexts." Journal of Marketing 87, no. 4 (July 2023): 618–635.
      • ←
      • 5
      • 6
      • …
      • 49
      • 50
      • →

      Are you looking for?

      →Search All HBS Web
      ǁ
      Campus Map
      Harvard Business School
      Soldiers Field
      Boston, MA 02163
      →Map & Directions
      →More Contact Information
      • Make a Gift
      • Site Map
      • Jobs
      • Harvard University
      • Trademarks
      • Policies
      • Accessibility
      • Digital Accessibility
      Copyright © President & Fellows of Harvard College.